Abstract
Thirteen patients in the predialysis phase of chronic renal failure (CRF) were treated with calcitriol (0.25 micrograms/day) and 12 with placebo. After 1 year of study, an increase in bone mineral density in the calcitriol group measured by dual-energy X-ray absorptiometry was seen for the femoral neck and lumbar spine when compared to the placebo group (p < 0.001 and p < 0.01, respectively). We conclude that a steady low dose of calcitriol started in the predialysis phase of CRF is beneficial to the patients with CRF. This may be partly due to suppression of secondary hyperparathyroidism.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Absorptiometry, Photon
-
Adult
-
Aged
-
Bone Density / drug effects*
-
Calcitriol / blood
-
Calcitriol / therapeutic use*
-
Double-Blind Method
-
Female
-
Humans
-
Hyperparathyroidism, Secondary / prevention & control
-
Kidney Failure, Chronic / drug therapy*
-
Kidney Failure, Chronic / metabolism
-
Kidney Failure, Chronic / therapy
-
Male
-
Middle Aged
-
Osteocalcin / blood
-
Parathyroid Hormone / blood
-
Peritoneal Dialysis, Continuous Ambulatory
-
Phosphorus / blood
-
Time Factors
Substances
-
Parathyroid Hormone
-
Osteocalcin
-
Phosphorus
-
Calcitriol